Long-term outcomes of below-the-knee bypass surgery using heparin-bonded expanded polytetrafluoroethylene grafts.

IF 1.7 4区医学 Q2 SURGERY

Surgery Today Pub Date : 2024-07-17 DOI:10.1007/s00595-024-02898-8

Yohei Yamamoto, Hidetoshi Uchiyama, Masahiro Oonuki, Kazuki Tsukuda, Ai Kazama, Yoshiki Wada, Hiroki Uchiyama, Toru Kikuchi, Masato Nishizawa, Toshifumi Kudo

{"title":"Long-term outcomes of below-the-knee bypass surgery using heparin-bonded expanded polytetrafluoroethylene grafts.","authors":"Yohei Yamamoto, Hidetoshi Uchiyama, Masahiro Oonuki, Kazuki Tsukuda, Ai Kazama, Yoshiki Wada, Hiroki Uchiyama, Toru Kikuchi, Masato Nishizawa, Toshifumi Kudo","doi":"10.1007/s00595-024-02898-8","DOIUrl":null,"url":null,"abstract":"Purpose: To report the outcomes of below-the-knee (BK) bypass surgery using heparin-bonded expanded polytetrafluoroethylene (ePTFE) grafts, performed in two centers since its launch in Japan.Methods: We conducted a retrospective analysis of databases from two medical centers, evaluating 51 limbs in 42 consecutive patients with peripheral arterial disease (PAD), who underwent BK bypass surgery using heparin-bonded ePTFE grafts between October, 2013 and April, 2023.Results: Thirty-three limbs (64.7%) were classified as Rutherford category 4-6 and 33 limbs (64.7%) had a history of ipsilateral revascularization. Technical success was achieved in 98% of the patients. The 30 day mortality rate was 2.4% (n = 1) and the overall 30 day complication rate was 9.5% (n = 4). The median follow-up period was 38 (interquartile range 13-67) months. Three patients required major amputation and 14 died during follow-up. Primary patency rates at 1, 3, and 5 years were 67.8%, 57.5%, and 46.5%, respectively, while secondary patency rates for these periods were 84.6%, 70.0%, and 66.0%, respectively. Overall survival rates at 1, 3, and 5 years were 90.1%, 74.5%, and 70.9%, respectively.Conclusions: BK bypass surgery using heparin-bonded ePTFE graft is a viable and durable option for patients with PAD, who are deemed unsuitable for autologous vein bypass surgery.","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-024-02898-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To report the outcomes of below-the-knee (BK) bypass surgery using heparin-bonded expanded polytetrafluoroethylene (ePTFE) grafts, performed in two centers since its launch in Japan.

Methods: We conducted a retrospective analysis of databases from two medical centers, evaluating 51 limbs in 42 consecutive patients with peripheral arterial disease (PAD), who underwent BK bypass surgery using heparin-bonded ePTFE grafts between October, 2013 and April, 2023.

Results: Thirty-three limbs (64.7%) were classified as Rutherford category 4-6 and 33 limbs (64.7%) had a history of ipsilateral revascularization. Technical success was achieved in 98% of the patients. The 30 day mortality rate was 2.4% (n = 1) and the overall 30 day complication rate was 9.5% (n = 4). The median follow-up period was 38 (interquartile range 13-67) months. Three patients required major amputation and 14 died during follow-up. Primary patency rates at 1, 3, and 5 years were 67.8%, 57.5%, and 46.5%, respectively, while secondary patency rates for these periods were 84.6%, 70.0%, and 66.0%, respectively. Overall survival rates at 1, 3, and 5 years were 90.1%, 74.5%, and 70.9%, respectively.

Conclusions: BK bypass surgery using heparin-bonded ePTFE graft is a viable and durable option for patients with PAD, who are deemed unsuitable for autologous vein bypass surgery.

Abstract Image

查看原文本刊更多论文

使用肝素粘合膨体聚四氟乙烯移植物进行膝下搭桥手术的长期疗效。

目的：报告使用肝素粘合膨体聚四氟乙烯（ePTFE）移植物的膝下（BK）搭桥手术的疗效：我们对两家医疗中心的数据库进行了回顾性分析，评估了在 2013 年 10 月至 2023 年 4 月期间使用肝素粘合膨体聚四氟乙烯（ePTFE）移植物接受 BK 搭桥手术的 42 名连续外周动脉疾病（PAD）患者的 51 条肢体：33条肢体（64.7%）被归类为卢瑟福4-6类，33条肢体（64.7%）有同侧血管再通史。98%的患者取得了技术成功。30天死亡率为2.4%（1例），30天并发症总发生率为9.5%（4例）。随访时间中位数为 38 个月（四分位数间距为 13-67 个月）。随访期间，3 名患者需要截肢，14 名患者死亡。1年、3年和5年的初次通畅率分别为67.8%、57.5%和46.5%，而这些时期的二次通畅率分别为84.6%、70.0%和66.0%。1年、3年和5年的总存活率分别为90.1%、74.5%和70.9%：结论：对于不适合进行自体静脉搭桥手术的 PAD 患者来说，使用肝素粘合 ePTFE 移植的 BK 搭桥手术是一种可行且持久的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgery Today 医学-外科

CiteScore

4.90

自引率

4.00%

发文量

208

审稿时长

1 months

期刊介绍： Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it"). The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.